Compare IDEXX Laboratories, Inc. (IDXX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Royal Bank of Canada — how do they compare? IDEXX Laboratories, Inc. trades at $552.09 (market cap $44.48B), while Royal Bank of Canada trades at $211.04 (market cap $289.51B). The key difference: Royal Bank of Canada is far larger — about 6.5× IDEXX Laboratories, Inc.'s market cap, and Royal Bank of Canada pays a 2.42% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | RY | |
|---|---|---|
Market Cap | $44.48B | $289.51B |
Sector | Health | Financials |
52-Week High | $766.68 | $217.87 |
52-Week Low | $520.87 | $128.46 |
Enterprise Value | $45.38B | — |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Royal Bank of Canada (RY) trades at $210.37, down 2.35% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent financial performance includes robust revenue growth to $66.53B in 2025 and a healthy net income margin of 31.85%, while the company maintains a solid dividend program with recent increases.
RY presents a mixed outlook with strong fundamentals and analyst support but faces valuation concerns. The company's consistent earnings beats and shareholder returns through dividends and buybacks provide upside potential, though elevated P/E and P/S ratios warrant caution. Key risks include economic sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
